ClinicalTrials.gg
RecruitingNCT07754214Updated Aug 20, 2026

Outcomes of the Proprioception and Strengthening Exercise Program in Chronic Plantar Fasciitis

An interventional study of Stretching and Proprioception and Stretching Exercises in Plantar Fasciitis, Chronic, sponsored by Karamanoğlu Mehmetbey University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Karamanoğlu Mehmetbey University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Plantar fasciitis is a common cause of heel pain, and although stretching exercises are a standard first-line treatment, current evidence on adding proprioception or knee-strengthening exercises remains limited. This study investigates whether adding knee strengthening or proprioception exercises to a standard stretching program improves pain, function, and disability in patients with chronic plantar fasciitis, and whether these interventions produce measurable changes in the biomechanical and kinesiological properties of the foot, ankle, and knee.

Read the detailed description

Plantar fasciitis is a degenerative condition of the plantar fascia and one of the most common musculoskeletal disorders affecting the foot, with an estimated prevalence of approximately 10% in the general population. It is diagnosed clinically based on history and physical examination, typically presenting as sharp heel pain during the first steps in the morning or after rest, tenderness on palpation of the medial calcaneal tuberosity, and a positive Windlass test. Risk factors include reduced ankle and first metatarsophalangeal joint range of motion, obesity, prolonged weight-bearing, and inappropriate footwear.

Stretching of the plantar fascia and gastrocnemius-soleus complex is a well-established, evidence-based treatment for plantar fasciitis. However, the underlying mechanism of the condition cannot be fully explained by tissue shortening and mechanical loading alone; impaired neuromuscular control and balance also appear to play a contributory role. Prior research has found that adding hip- and ankle-directed strengthening exercises to a stretching program provides no additional benefit over stretching alone in patients with plantar fasciitis, while other studies have reported reduced hamstring and quadriceps muscle strength in this population. Individuals with plantar fasciitis have also been shown to exhibit impaired postural balance and an increased risk of falls. While proprioception exercises have demonstrated benefit in the rehabilitation of ankle injuries, their effectiveness has not yet been established in plantar fasciitis. Given these gaps, this study aims to evaluate whether knee-strengthening and proprioception exercises, when added to a standard stretching program, provide additional benefit in reducing pain and disability and improving the biomechanical and kinesiological properties of the foot, ankle, and knee in patients with plantar fasciitis.

02

Conditions studied

  • Plantar Fasciitis, Chronic

Browse trials for

Keywords

  • plantar fasciitis
  • strengthening
  • stretching
  • proprioception
  • chronic plantar fasciitis
03

In context

Fasciitis, Plantar

223 studies on the registry are indexed under Fasciitis, Plantar; 58 are open to participants now.

This study's planned enrollment of 105 is above the median of 56 across 194 interventional studies indexed under Fasciitis, Plantar.

Browse Fasciitis, Plantar studies →

Lead sponsor

Karamanoğlu Mehmetbey University is the lead sponsor of 69 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years.
  • Formal diagnosis of plantar fasciitis, characterized by sharp pain during the first steps in the morning, pain that increases with prolonged activity, localized tenderness on palpation of the medial calcaneal tubercle or proximal fascia, and a positive Windlass test.
  • Symptom duration of at least 3 months.
  • Heel pain intensity score of Visual Analog Scale (VAS) > 3.
  • Voluntary agreement to participate, evidenced by signing the written form.

Exclusion criteria

Exclusion Criteria:

  • History of acute lower-extremity trauma.
  • History of prior foot or ankle surgery.
  • injection to the affected heel within the preceding 6 months.
  • Presence of systemic inflammatory or rheumatologic disease.
  • Uncontrolled systemic disease (e.g., uncontrolled hypertension, uncontrolled diabetes mellitus).
  • Current or past history of .
  • Current pregnancy.
  • (BMI) ≥ 30 kg/m².
  • Any musculoskeletal, neuromuscular, ocular, or vestibular disorder that could impair balance or limit the ability to stand unsupported.
  • Neurocognitive or psychiatric conditions precluding adherence to the exercise protocols or outcome assessments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Active comparator
    Stretching Only

    This group will perform plantar fascia-gastrocnemius-soleus stretching exercises alone (twice daily, 7 days per week, for 6 weeks).

    Other: Stretching

  • Experimental
    Stretching and Proprioception

    In addition to the standard stretching program, this group will receive supervised proprioception exercises three times per week for 6 weeks.

    Other: Proprioception and Stretching Exercises

  • Experimental
    Stretching and Knee Strengthening

    In addition to the standard stretching program, this group will receive supervised knee strengthening exercises three times per week for 6 weeks.

    Other: Knee Strengthening and Stretching Exercises

Interventions

  • OtherStretching

    Participants will perform standardized plantar fascia and gastrocnemius-soleus stretching exercises. The protocol consists of stretching twice daily, 7 days per week, for 6 weeks.

  • OtherProprioception and Stretching Exercises

    In addition to the standard stretching protocol, participants in this group will perform a supervised, 6-week progressive proprioception exercise program administered by a physiotherapist three times per week. Exercises will be performed under both eyes-open and eyes-closed conditions on progressively less stable surfaces with task difficulty advanced on a weekly basis.

  • OtherKnee Strengthening and Stretching Exercises

    In addition to the standard stretching protocol, participants in this group will perform a supervised, 6-week progressive knee-strengthening program administered by a physiotherapist three times per week.

06

What researchers measure

Primary outcomes

  1. Pain Intensity (First-Step Morning, Evening, and Overall Daily Pain)

    Pain intensity during the first steps in the morning, before going to bed, and overall daily pain will be assessed using the Visual Analog Scale (VAS). The scale consists of a 10-cm horizontal line ranging from 0 (no pain) to 10 (worst imaginable pain), on which participants mark the point corresponding to their perceived pain level.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  2. Pressure Pain Threshold (PPT)

    PPT will be assessed using a Baseline® 12-1442 dolorimeter (22-lb sensitivity range; Fabrication Enterprises Inc., USA) to evaluate deep-tissue mechanical sensitivity. With the participant positioned prone and the feet hanging off the table, gradually increasing pressure will be applied to the midpoint of the plantar fascia insertion at the calcaneus. The pressure at which the participant first perceives pain will be recorded. Three measurements will be taken at 30-second intervals, and the mean value will be used for analysis.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  3. Foot Function and Health Status (Revised Foot Function Index, FFI-R)

    The FFI-R is a self-reported, multidimensional questionnaire comprising 68 items across four subscales: pain and stiffness, social and emotional consequences, dysfunction, and activity limitation. Each item is scored from 1 to 4, with higher scores indicating poorer foot health and greater functional limitation.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  4. Foot and Ankle Function (Foot and Ankle Outcome Score, FAOS)

    The FAOS is a 42-item self-reported questionnaire assessing five subscales: pain, other symptoms, activities of daily living, sports and recreation, and foot-and-ankle-related quality of life. Each item is scored from 0 to 4.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

Secondary outcomes

  1. Myofascial Tissue Biomechanical Properties

    The biomechanical and viscoelastic properties of the plantar fascia, Achilles tendon, gastrocnemius medialis, soleus, biceps femoris, semitendinosus, tibialis anterior, vastus lateralis, vastus medialis, and rectus femoris will be assessed non-invasively using the MyotonPRO device (Myoton AS, Tallinn, Estonia). The device will be positioned perpendicular to the anatomical landmark of each muscle; upon delivery of a mechanical impulse, it automatically calculates muscle tone (Hz), stiffness (N/m), and elasticity (logarithmic decrement). The mean of three consecutive measurements will be recorded.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  2. Plantar Fascia Ultrasonographic Parameters

    Musculoskeletal ultrasonography (GE Logiq® P5 system; GE Healthcare, USA) will be used to evaluate structural changes. Plantar fascia thickness will be measured longitudinally at 0.5 cm, 1 cm, and 3 cm distal to the calcaneal insertion. Qualitative parameters, including tissue echogenicity, perifascial fluid accumulation, and calcifications, will also be recorded.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  3. Ankle Dorsiflexion Range of Motion (ROM)

    Weight-bearing ankle dorsiflexion ROM will be measured in degrees using a Baseline® 12-1057 digital inclinometer (0.1° resolution; Fabrication Enterprises Inc., USA), positioned parallel to the long axis of the tibia over the tibial tuberosity during a weight-bearing lunge test. The mean of three measurements will be recorded.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  4. First Metatarsophalangeal (MTP) Joint Range of Motion

    Maximum active dorsiflexion and flexion angles of the first MTP joint will be measured in degrees using a finger goniometer with the participant in a supine position. The mean of three measurements will be recorded.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  5. Joint Position Sense (JPS) (Ankle-Knee and Hip)

    Proprioceptive accuracy will be assessed at the ankle, knee, and hip joints via active joint position reproduction testing using a Baseline® 12-1057 digital inclinometer. For the ankle, participants will actively reproduce target dorsiflexion/plantarflexion angles. For the knee, participants will actively reproduce a target angle starting from 90° of flexion, with the inclinometer fixed to the middle third of the leg. For the hip, participants will actively reproduce target angles for flexion (assessed in supine position) and abduction (assessed in side-lying position), with the inclinometer fixed to the lateral aspect of the thigh. For each joint, the absolute error angle (the difference between the target angle and the actively reproduced angle) will be recorded across three trials, and the mean absolute error angle will be calculated as the outcome value. Lower values indicate better proprioceptive accuracy.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  6. Isometric Muscle Strength of the Lower Extremity

    Isometric muscle strength for ankle (dorsiflexion, plantarflexion) and knee (extension, flexion) movements will be measured using a Lafayette® Hand-Held Dynamometer (Model 01165; Lafayette Instrument Company, USA), with standardized testing positions and stabilization protocols. Peak force will be recorded in Newtons (N) as the mean of three maximal isometric contractions.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  7. Static Balance

    Static postural control will be assessed using the Single-Leg Stance Test (SLST) under eyes-open and eyes-closed conditions. The duration (in seconds) for which the participant maintains single-leg balance without touching the ground or the supporting leg will be recorded. Mean durations of three trials will be analyzed.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

  8. Dynamic Balance

    Dynamic balance and lower-extremity postural control will be evaluated using the Y-Balance Test (YBT). Maximum reach distances in the anterior, posteromedial, and posterolateral directions will be measured in centimeters and normalized to lower-limb length (LL). The composite score (%) will be calculated as: \[(Anterior + Posteromedial + Posterolateral) / (3 × LL)\] × 100.

    Time frame: Baseline (Week 0), post-intervention (Week 6), and follow-up (Week 12).

07

Study locations

1 of 1 sites recruiting
  • Karaman Training and Research Hospital
    Karaman, Karaman 70100, Turkey (Türkiye)
    Recruiting
    • Sule Kosar, MD · Contactsulekosar@kmu.edu.tr · +90 506 145 9656
    • Aynur Basaran, Prof.MD · Contactaynurbasaran@gmail.com · +90 537 562 06 66
    • Aynur Basaran, MD, Prof. · Principal investigator
    • Ummahani Kus, MSc, PT · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 104 non-industry interventional studies with no phase under Fasciitis, Plantar, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's planned 4 months is below that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Aug 10, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07754214
Lead sponsor
Karamanoğlu Mehmetbey University
Responsible party
Sule Kosar (Resident, Physical Medicine and Rehabilitation, Karamanoğlu Mehmetbey University) — Principal investigator
First posted
Aug 10, 2026
Start date
Aug 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 20, 2026

Study contacts

Sule Kosar, MD
Contact
sulekosar@kmu.edu.tr
+90 506 145 9656
Aynur Basaran, Prof. MD
Contact
aynurbasaran@gmail.com
+90 537 562 06 66
Aynur Basaran, MD, Prof.
principal investigator · Karamanoğlu Mehmetbey University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion